Press release
Myasthenia Gravis Market Expected to Witness Substantial Growth by 2034, Driven by Recent FDA Approvals and Positive Clinical Trial Outcomes | DelveInsight
Myasthenia Gravis - Market Insight, Epidemiology And Market Forecast - 2034
DelveInsight's "Myasthenia Gravis - Market Insight, Epidemiology And Market Forecast - 2034 [https://www.delveinsight.com/report-store/myasthenia-gravis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]" report provides comprehensive insights into the historical and forecasted myasthenia gravis epidemiology, as well as market trends across the 7MM (United States, EU4 countries including Germany, France, Italy, and Spain, along with the United Kingdom, and Japan). The myasthenia gravis market size in the 7MM reached approximately USD 5 billion in 2023, with projections indicating substantial growth throughout the forecast period (2024-2034). This expansion is primarily driven by increasing disease prevalence, enhanced diagnostic capabilities, and the anticipated launch of novel therapeutic options targeting specific disease mechanisms.
According to DelveInsight's analysis, the US dominated the myasthenia gravis market in 2023, representing nearly 76% of the total market share. This dominance is attributed to favorable reimbursement policies, high healthcare expenditure, and rapid adoption of innovative therapies. The EU4 countries and the United Kingdom collectively form the second-largest market, followed by Japan, which is expected to experience significant growth during the forecast period.
Download the Myasthenia Gravis Market Forecast Report to understand which factors are driving the Myasthenia Gravis market @ Myasthenia Gravis Market Trends [https://www.delveinsight.com/sample-request/myasthenia-gravis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
The report also delivers detailed epidemiological insights, indicating that total diagnosed myasthenia gravis prevalent cases across 7MM were approximately 300K in 2023, with the US accounting for approximately 130K cases. EU4 and the UK together accounted for nearly 125K diagnosed prevalent cases, while Japan reported a little more than 32K cases. These figures are projected to increase at a notable CAGR throughout the study period (2020-2034).
Discover evolving trends in the Myasthenia Gravis patient pool forecasts @ Myasthenia Gravis Epidemiological Analysis [https://www.delveinsight.com/sample-request/myasthenia-gravis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
The current myasthenia gravis treatment landscape encompasses cholinesterase enzyme inhibitors, immunosuppressive medications, and biological therapies. VYVGART (efgartigimod alfa-fcab), developed by Argenx, has established itself as a groundbreaking FcRn blocker approved in multiple regions for treating generalized myasthenia gravis in adults who are anti-acetylcholine receptor antibody-positive. Other significant therapies in the market include SOLIRIS and ULTOMIRIS, manufactured by Alexion Pharmaceuticals, which have demonstrated efficacy in managing refractory cases.
The myasthenia gravis pipeline is robust, with several promising therapies in late-stage clinical development. Batoclimab from Immunovant Sciences GmbH has shown positive results in Phase III studies, demonstrating significant improvements in Myasthenia Gravis Activities of Daily Living (MG-ADL) scores. Additionally, DESCARTES-08, Cartesian Therapeutics' RNA CAR T-cell therapy specifically designed for autoimmune diseases, represents an innovative approach in the treatment paradigm.
In a notable recent development, Cartesian Therapeutics announced in January 2025 that it received a written agreement from the FDA under the Special Protocol Assessment (SPA) process for the design of its planned Phase III AURORA trial for Descartes-08, its lead mRNA cell therapy candidate targeting myasthenia gravis. This milestone underscores the evolving treatment landscape and highlights the industry's commitment to addressing the unmet medical needs of the myasthenia gravis patient population.
Additionally, in April 2025, the FDA approved Johnson & Johnson's nipocalimab, marketed as IMAAVY, as a new treatment for adults and pediatric patients aged 12 years and older who have generalized myasthenia gravis and are anti-acetylcholine receptor or anti-muscle-specific kinase antibody positive.
Promising myasthenia gravis therapeutic updates also include positive outcomes and steroid-sparing effects from inebilizumab. Furthermore, new safety and efficacy data have emerged for efgartigimod, rozanolixizumab, nipocalimab, and complement inhibitors such as zilucoplan and ravulizumab.
Discover evolving trends in the Myasthenia Gravis treatment landscape @ Myasthenia Gravis Recent Developments [https://www.delveinsight.com/sample-request/myasthenia-gravis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
DelveInsight's analysis indicates that the myasthenia gravis market is highly competitive and rapidly evolving, with leading pharmaceutical companies such as Roche (SWX: ROG), UCB Pharma (EBR: UCB), Alexion Pharmaceuticals (NASDAQ: ALXN), Mitsubishi Tanabe Pharma (MTZPY), Sanofi (EPA: SAN), Grifols (BME: GRF), Amgen (NASDAQ: AMGN), Eisai (TYO: 4523), Merck & Co. (NYSE: MRK), Novartis (SWX: NOVN), GlaxoSmithKline (LON: GSK), AbbVie (NYSE: ABBV), Teva Pharmaceutical (TLV: TEVA), Sandoz (SWX: SDZ), Argenx (EBR: ARGX), Bristol-Myers Squibb (NYSE: BMY), and Catalysts Pharmaceuticals (NASDAQ: CPRX), among others, are actively developing and marketing treatments.
The integration of innovative treatment modalities, including FcRn inhibitors and cell therapies, is expected to significantly improve patient outcomes in this rare autoimmune neuromuscular disorder characterized by muscle weakness and fatigue. However, challenges such as high treatment costs and limited accessibility in certain regions continue to impact market dynamics.
As research advances and clinical trials progress, the myasthenia gravis market is expected to witness a paradigm shift in treatment approaches, moving toward more personalized therapeutic strategies based on antibody serological profiles and disease severity classifications. This evolution, coupled with increasing disease awareness and improved diagnostic capabilities, will continue to drive market growth and address the myasthenia gravis patients unmet needs.
Table of Contents
1. Key Insights
2. Report Introduction
3. Myasthenia Gravis Market Overview at a Glance
4. Epidemiology and Market Forecast Methodology
5. Executive Summary
6. Key Events
7. Disease Background and Overview
8. Myasthenia Gravis Epidemiology and Patient Population
9. Myasthenia Gravis Patient Journey
10. Myasthenia Gravis Marketed Therapies
11. Myasthenia Gravis Emerging Therapies
12. Myasthenia Gravis: Market Analysis
13. Key Opinion Leaders' Views
14. SWOT Analysis
15. Myasthenia Gravis Unmet Needs
16. Market Access and Reimbursement
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight
Related Reports
Myasthenia Gravis Pipeline Insight [https://www.delveinsight.com/sample-request/myasthenia-gravis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]
Myasthenia Gravis Pipeline Insight provides comprehensive insights about the Myasthenia Gravis pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Myasthenia Gravis companies, including Harbour BioMed (Guangzhou) Co. Ltd., Kyverna Therapeutics, Cabaletta Bio, Takeda, Hoffmann-La Roche, Immunovant Sciences GmbH, Regeneron Pharmaceuticals, Novartis Pharmaceuticals, Janssen Research & Development, LLC, Momenta Pharmaceuticals, Inc., Amgen, Dianthus Therapeutics, Cartesian Therapeutics, COUR Pharmaceutical Development Company, Inc., and Alexion Pharmaceuticals Inc, among others.
About DelveInsight
DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=myasthenia-gravis-market-expected-to-witness-substantial-growth-by-2034-driven-by-recent-fda-approvals-and-positive-clinical-trial-outcomes-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Myasthenia Gravis Market Expected to Witness Substantial Growth by 2034, Driven by Recent FDA Approvals and Positive Clinical Trial Outcomes | DelveInsight here
News-ID: 4006038 • Views: …
More Releases from ABNewswire
Is Couples Therapy Right? Signs It's Time to See a Counsellor in Birmingham
Relationships can be both fulfilling and challenging. No matter how strong a couple may seem on the outside, it's natural to face hurdles along the way. Miscommunication, stress, life changes, or unresolved issues can create distance between partners. While every couple goes through ups and downs, knowing when to seek professional support can make all the difference. If you've ever found yourself searching for "couples therapy near me" or wondering…
Rialto-Based Get it from Bo Pioneers Collaborative E-Commerce Model Supporting M …
Get it from Bo revolutionizes online retail through strategic manufacturer partnerships that deliver quality products at reasonable prices. The California-based platform, established in 2024, creates sustainable business relationships while expanding inventory daily to serve diverse consumer needs.
Get it from Bo is establishing new standards in the e-commerce industry through its innovative collaborative approach that prioritizes sustainable partnerships with manufacturers and brands while delivering exceptional value to consumers. The Rialto, California-based…
Daily Vibe Launches Comprehensive Fitness Products Store for Diverse Consumer Ma …
New fitness retailer Daily Vibe enters the market with targeted product selections designed to support active lifestyles across multiple demographics. The startup focuses on serving fitness enthusiasts, health-conscious consumers, and older adults seeking quality fitness products.
Founded by Ja'von L. Watson and Joyleena S. Watson, AGAIT International is a fast-growing Atlanta-based tech company dedicated to solving social and economic challenges through creative business and digital solutions. The company develops and manages…
Prolift Handling Brings Advanced pewag Lifting Technology to Ireland
Prolift Handling launches pewag levo Balancer and levo Compensator in Ireland - two advanced lifting solutions that improve safety and precision in heavy lifting operations through remote-controlled positioning and automatic load balancing.
Dublin, Ireland - Sep 30, 2025 - Prolift Handling, Ireland's exclusive pewag partner, today launched two advanced lifting solutions designed to tackle the industry's most challenging safety and precision requirements: the pewag levo Balancer and pewag levo Compensator.
The pewag…
More Releases for Myasthenia
Myasthenia Gravis (MG) Treatment Market: Insights and Trends
The Global Myasthenia Gravis (MG) Treatment Market is experiencing notable growth, driven by increasing awareness of the disease and advancements in treatment options. Myasthenia Gravis is a chronic autoimmune disorder that leads to varying degrees of muscle weakness, and effective management is crucial for improving patient quality of life.
With ongoing research and development in treatment modalities, the market is poised for significant expansion over the coming years.
Market Size and Growth:
The…
Myasthenia Gravis Market | Rising Prevalence Of Neuromuscular Disorders
According to Precision Business Insights (PBI), the latest report, the Myasthenia Gravis market is expected to be valued at USD 1,734.6 million in 2022, growing at an 8.1% CAGR from 2022 to 2028. The primary driver of the expansion of the global Myasthenia Gravis market increasing prevalence of neuromuscular disorders, and rising awareness about effective treatment.
View the detailed report description here - https://precisionbusinessinsights.com/market-reports/myasthenia-gravis-market/
Medication Segment to Dominate the Myasthenia…
Myasthenia Gravis - Drug Pipeline Landscape, 2022
Myasthenia gravis is a chronic autoimmune neuromuscular condition that causes muscle weakness and severe fatigue. It causes weakness in the skeletal muscles, which are the muscles your body uses for movement. Myasthenia gravis is caused by a breakdown in the normal communication between nerves and muscles.
Healthcare professional checks neurological health by testing reflexes, muscle strength, muscle tone etc. Ice pack test, antibody tests, imaging scans and electromyogram can also be…
Myasthenia Gravis Industry Report Analysis By opportunities
Stratistics MRC's Myasthenia Gravis Market report provides readers with an understanding of market details, overview, drivers and segmentation with types.
Myasthenia gravis is a chronic autoimmune neuromuscular disorder that is characterized by variable weakness of the voluntary muscle groups. Muscles that observe eye movement, shoulder & facial muscles, breathing & swallowing and eye lids are the ones that are regularly impacted in myasthenia gravis.
Browse complete "Myasthenia Gravis Market" report with TOC…
Myasthenia Gravis Industry Report Analysis By opportunities
Stratistics MRC's Myasthenia Gravis Market report provides readers with an understanding of market details, overview, drivers and segmentation with types.
Myasthenia gravis is a chronic autoimmune neuromuscular disorder that is characterized by variable weakness of the voluntary muscle groups. Muscles that observe eye movement, shoulder & facial muscles, breathing & swallowing and eye lids are the ones that are regularly impacted in myasthenia gravis.
Browse complete "Myasthenia Gravis Market" report with TOC…
Global Myasthenia Gravis Industry Analysis By Geography
Stratistics MRC's Myasthenia Gravis Market report explains company profiling, key segments, market trends, top players and regional, country-level segments.
Myasthenia gravis is a chronic autoimmune neuromuscular disorder that is characterized by variable weakness of the voluntary muscle groups. Muscles that observe eye movement, shoulder & facial muscles, breathing & swallowing and eye lids are the ones that are regularly impacted in myasthenia gravis.
Browse complete "Myasthenia Gravis Market" report with TOC @…
